Exiris

Exiris is an Italian preclinical biotech founded by former Merck & Co. scientists to address high unmet needs in oncology. The company's core strategy revolves around three proprietary platforms: a Cancer Stem Cell (CSC) platform for target discovery, an Antibody ID phage display library for fully human antibody generation, and a Drug Conjugate technology. Exiris aims to advance its own discoveries to preclinical proof-of-concept before seeking partners for clinical development, while simultaneously generating revenue through fee-for-service research and co-development deals.

Proprietary combination of a Cancer Stem Cell (CSC) platform for target identification, an Antibody ID phage display library for fully human antibody generation, and a Drug Conjugate technology for creating potent antibody/peptide-drug conjugates.

Exiris competes in the crowded fields of antibody discovery and ADC platform technology with numerous larger biotechs and pharma. Its differentiation lies in the integration of its CSC-based target discovery, which is a specialized niche. For CRO services, it competes with large global CROs and specialized oncology research providers.